Daniela Coltrini

Daniela Coltrini

Auto-generated profile, based on publicly available information

Daniela Coltrini

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MBMirella Belleri
Mirella Belleri
GPGiuseppe Paganini
Giuseppe Paganini
DCDaniela Coltrini
Daniela Coltrini
RRRoberto Ronca
Roberto Ronca
DZDaniela Zizioli
Daniela Zizioli
Marco PrestaMarco Presta
Marco Presta
Disturbance of sphingolipid metabolism may represent a novel therapeutic target in metastatic melanoma, the most lethal form of skin cancer. β-Galactosylceramidase (GALC) removes β-galactose from galactosylceramide and other sphingolipids. In this study, we show that downregulation of galcb, a zebrafish ortholog of human GALC, affects melanoblast and melanocyte differentiation in zebrafish embryos, suggesting a possible role for GALC in melanoma. On this basis, the impact of GALC expression in murine B16-F10 and human A2058 melanoma cells was investigated following its silencing or upregulation. Galc knockdown hampered growth, motility, and invasive capacity of B16-F10 cells and their tumorigenic and metastatic activity when grafted in syngeneic mice or zebrafish embryos. Galc-silenced cells displayed altered sphingolipid metabolism and increased intracellular levels of ceramide, paralleled by a nonredundant upregulation of Smpd3, which encodes for the ceramide-generating enzyme neutral sphingomyelinase 2. Accordingly, GALC downregulation caused SMPD3 upregulation, increased ceramide levels, and inhibited the tumorigenic activity of human melanoma A2058 cells, whereas GALC upregulation exerted opposite effects. In concordance with information from melanoma database mining, RNAscope analysis demonstrated a progressive increase of GALC expression from common nevi to stage IV human melanoma samples that was paralleled by increases in microphthalmia transcription factor and tyrosinase immunoreactivity inversely related to SMPD3 and ceramide levels. Overall, these findings indicate that GALC may play an oncogenic role in melanoma by modulating the levels of intracellular ceramide, thus providing novel opportunities for melanoma therapy. Significance: Data from zebrafish embryos, murine and human cell melanoma lines, and patient-derived tumor specimens indicate that β-galactosylceramidase plays an oncogenic role in melanoma and may serve as a therapeutic target.

1 April 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MCMarianna Cerasuolo
Marianna Cerasuolo
FMFederica Maccarinelli
Federica Maccarinelli
DCDaniela Coltrini
Daniela Coltrini
AMAli Mahmoud
Ali Mahmoud
VMViviana Marolda
Viviana Marolda
RRRoberto Ronca
Roberto Ronca
Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in patients previously exposed to chemotherapy. However, resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that may delay or prevent the onset of resistance. In this study, the prostate cancer multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a multiscale stochastic mathematical model was proposed to link the in vitro and in vivo evolution of prostate cancer. The model showed that all therapeutic strategies that use enzalutamide result in the onset of resistance. The model also showed that combination therapies can delay the onset of resistance to enzalutamide, and in the best scenario, can eliminate the disease. These results set the basis for the exploitation of this “TRAMP-based platform” to test novel therapeutic approaches and build further mathematical models of combination therapies to treat prostate cancer and CRPC. Significance: Merging mathematical modeling with experimental data, this study presents the “TRAMP-based platform” as a novel experimental tool to study the in vitro and in vivo evolution of prostate cancer resistance to enzalutamide.

31 March 2023
Verified
Other
Open access
MBMirella Belleri
Mirella Belleri
GPGiuseppe Paganini
Giuseppe Paganini
DCDaniela Coltrini
Daniela Coltrini
RRRoberto Ronca
Roberto Ronca
DZDaniela Zizioli
Daniela Zizioli
Marco PrestaMarco Presta
Marco Presta
Supplementary Data - Single file with supplemental methods, tables, figures, legends. Supplemental Materials and Methods; Table S1: Primers used for RT-qPCR analysis; Table S2: GALC downregulation affects the lipid profile of murine B16-F10 melanoma cells; Table S3: Expression levels of enzymes involved in sphingolipid metabolism in B16-F10 cells; Table S4: RT-qPCR analysis of the expression of tumor infiltrate markers and immune checkpoints in B16-F10 tumor grafts; Figure S1: Galca does not affect melanocyte differentiation in zebrafish; Figure S2: Galc downregulation does not affect cell cycle distribution and cell death in B16-F10 cells; Figure S3: The neutral sphingomyelinase inhibitor GW4869 increases the tumorigenic activity of shGALC-B16-F10 cells; Figure S4: Inhibition of the tumorigenic activity in shGALC-bis-B16-F10 cells; Figure S5: Public data mining of GALC expression in human melanoma; Figure S6: Public data mining of SMPD3 expression in human melanoma.

31 March 2023
Verified
Other
Open access
MCMarianna Cerasuolo
Marianna Cerasuolo
FMFederica Maccarinelli
Federica Maccarinelli
DCDaniela Coltrini
Daniela Coltrini
AMAli Mahmoud
Ali Mahmoud
VMViviana Marolda
Viviana Marolda
RRRoberto Ronca
Roberto Ronca
The Figure shows the long term behavior of sensitive and resistant cells (in absence of enzalutamide

31 March 2023
Verified
Other
Open access
MCMarianna Cerasuolo
Marianna Cerasuolo
FMFederica Maccarinelli
Federica Maccarinelli
DCDaniela Coltrini
Daniela Coltrini
AMAli Mahmoud
Ali Mahmoud
VMViviana Marolda
Viviana Marolda
RRRoberto Ronca
Roberto Ronca
Additional Material and Methods

31 March 2023
Verified
Other
Open access
MCMarianna Cerasuolo
Marianna Cerasuolo
FMFederica Maccarinelli
Federica Maccarinelli
DCDaniela Coltrini
Daniela Coltrini
AMAli Mahmoud
Ali Mahmoud
VMViviana Marolda
Viviana Marolda
RRRoberto Ronca
Roberto Ronca
Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in patients previously exposed to chemotherapy. However, resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that may delay or prevent the onset of resistance. In this study, the prostate cancer multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a multiscale stochastic mathematical model was proposed to link the in vitro and in vivo evolution of prostate cancer. The model showed that all therapeutic strategies that use enzalutamide result in the onset of resistance. The model also showed that combination therapies can delay the onset of resistance to enzalutamide, and in the best scenario, can eliminate the disease. These results set the basis for the exploitation of this “TRAMP-based platform” to test novel therapeutic approaches and build further mathematical models of combination therapies to treat prostate cancer and CRPC.Significance: Merging mathematical modeling with experimental data, this study presents the “TRAMP-based platform” as a novel experimental tool to study the in vitro and in vivo evolution of prostate cancer resistance to enzalutamide.